The majority of patients with stage III-IV epithelial ovarian cancer (EOC) relapse after initially responding to platinum-based chemotherapy, and develop resistance. The genomic features involved in drug resistance are unknown. To unravel some of these features, we investigated the mutational profile of genes involved in pathways related to drug sensitivity in a cohort of matched tumors obtained at first surgery (Ft-S) and second surgery (Sd-S).
the median progression-free survival (PFS) lasts only 18 months, and more than 80% of Pt-responsive patients relapse with a disease that progressively becomes Pt-resistant. They tend to die within 5 years from diagnosis [1] . Tumor stage, debulking status and Pt-free interval are the main prognostic parameters used in the clinical management of EOC, while the molecular characteristics correlated with patient outcome and response to therapy are unknown. Studies carried out so far in large cohorts of patients at both the genetic and epigenetic levels, failed to provide reliable predictive biomarkers to improve patient stratification, or genomic alterations critical for the development of a targeted approach against EOC [2] . With the exception of bevacizumab, there are currently no targeted biological therapies approved for treatment of ovarian carcinomas. Recently, treatment of EOC with PARP inhibitors (PARPi) has been considered based on homologous recombination (HR) status [3] [4] [5] . One reason for the scarcity of therapeutic options is the complex and heterogeneous molecular nature of EOC [6] . In addition, there is no molecular information available on tumor biology at relapse, as second debulking surgery for EOC is carried out in only a small fraction of patients who relapse. Thus, we currently do not know whether the molecular scenario connected with tumor relapse mirrors that in tissues obtained at primary surgery. Furthermore, the molecular drivers associated with relapse and resistance are unknown. This lack of knowledge intimates the urgent need to evaluate time-dependent proximal tumor markers for secondline chemotherapy in EOC, in analogy to the situation in breast and lung cancer [7] [8] [9] [10] .
To this end, 33 EOC patients from whom matched longitudinal biopsies were available were selected for the study, and the genomic evolution of 65 genes known to be involved in tumor progression and therapy response were investigated by nextgeneration sequencing (NGS) approach.
materials and methods patient cohort
A cohort of 33 EOC patients with matched primary surgery (Ft-S) and second surgery biopsies (Sd-S) was selected from the 'Pandora' tumor tissue collection, settled at 'Mario Negri' institute. The study has been carried out following the principles of the Declaration of Helsinki; the local scientific ethical committees approved the collection and usage of tumor samples. Written informed consent was obtained from all patients.
target re-sequencing libraries and massively parallel sequencing Sequences for selected 65 genes were generated using TrueSeq amplicon panel (TSCA, Illumina, Palo Alto, CA) as described in supplementary Section 1, available at Annals of Oncology online. Quantified libraries were sequenced on the MiSeq platform (Illumina) using the 2 × 150 bp configuration (300 cycles) and run on V2 sequencing flow cell. Details are reported in supplementary Section 2, available at Annals of Oncology online.
results

patient cohort
Target sequencing analysis was carried out on a cohort of 33 patients with matched Fs-S and Sd-S biopsies. Histological and clinical parameters at diagnosis (Table 1) show that all cases, except one, presented with advanced stage EOC, of whom 75% were high grade (HG, 25 of 33) and 25% low grade (LG, 8 of 33). The most frequent histotype was serous (n = 24, 72.7%), although endometrioid (n = 4, 12.1%), mucinous (n = 2, 6.1%), mixed (n = 2, 6.1%) and clear-cell histotypes (n = 1, 3%) were included. The mean age at diagnosis was 56 years with a mean follow-up of 4.5 years. Table 2 summarizes the clinical information including therapeutic strategies and response to therapy during the follow-up, according to response evaluation criteria in solid Tumors (RECIST) criteria [11] . Specimens were removed from ovaries at Ft-S, and from the peritoneal cavity (omentum or peritoneum) at Sd-S. While Pt-based therapy used to be the mainstay for EOC until recently, second line therapy options have been more varied. Therefore, our Sd-S collection is less homogeneous than the Ft-S collection (Table 2) . Detailed information is reported in supplementary Table S3 .1, available at Annals of Oncology online.
The workflow depicted in Figure 1 shows the details of our targeted re-sequencing approach and the two objectives of the study: (i) defining the evolution of the genomic architecture from Ft-S to Sd-S and (ii) defining the level of concordance in matched biopsies.
somatic variant call database
Our pipeline of analysis (supplementary Section 2, available at Annals of Oncology online) identified 2270 somatic variants functionally classified as single nucleotide polymorphism, both synonymous and nonsynonymous, indel or variant of unknown significance (VUS) for noncoding mutations mapping in intergenic regions, UTR or canonical splicing sites (Table 3) . Variants were with a wide inter/intraindividual variation: the average of somatic mutations per patient is 62.03 ± 40.6 at Ft-S and 37.72 ± 51.16 at Sd-S, with individual variation ranging from 25 to 178 at Ft-S and 4-253 at Sd-S (Table 3) . Seven hundred fifteen were nonsynonymous, 245 synonymous, 100 indels and 1210 as VUS (Table 3) . Synonymous mutations were then excluded from the analyses. Supplementary Figure S3 .1, available at Annals of Oncology online, shows that the number of transitions and transversions at Ft-S and Sd-S are comparable, while indels were more frequent in Ft-S than in Sd-S (Table 3 , supplementary Figure S3 .1, available at Annals of Oncology [12] . The NS/S ratio was >1 suggesting that mutations were selected under positive pressure, probably by chemotherapy at Sd-S or by tumor outgrowth at Ft-S. Unsupervised cluster analysis revealed a complex and heterogeneous architecture with poor association between matched Ft-S and Sd-S (supplementary Figure S3. 2, available at Annals of Oncology online).
mutation profile at Ft-S
The complex and heterogeneous results reported in supplementary Figure S3 .3, available at Annals of Oncology online, confounded the strategy to use unsupervised cluster analysis to stratify Ft-S biopsies based on genomic mutation profiles. The heatmap in Figure Table S3 .2, available at Annals of Oncology online). Signature validation confirmed the robustness of our analysis although droplet digital PCR data had a different sensitivity for mutations with allelic fraction (AF) ranging from 1% to 4% (supplementary Table S4 .3, available at Annals of Oncology online). Closer inspection revealed that ATM/ATR variants were very common in all patients, with median AF above 30% ( Figure 2B ), while the median AF for the BRCA1/2 gene ranges from 0.1% to 4% ( Figure 2B ). These results suggest that tumor biopsies comprise populations of cells containing largely identical somatic alterations in ATM/ATR genes, underlining the importance of moving beyond the classical BRCA1/2 analysis to correlate HR defects to treatment response.
matched Ft-S and Sd-S mutations
The second aim of our study was to identify concordant mutations. Figure 3A shows that clonal structure at relapse is more homogeneous than at Ft-S, as the number of somatic events, mainly indels (red bars), largely exceeded those counted at Sd-S ( paired t-test, P < 0.0001). In Table 3 , the term 'shared' defines those somatic loci found mutated in both Ft-S and in Sd-S, but not necessarily in matched biopsies. Somatic loci found mutated in matched biopsies have been defined as 'concordant' ( 
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Sd-s n = 33 Figure 1 . Workflow of the study. Thirty-three matched EOC tumor biopsies, taken before (Ft-S) and after chemotherapy (Sd-S) were selected, and 65 genes known to play role in pathways associated to tumor growth and therapy response were full-length sequenced. The bcbio-nextgen pipeline and the CLoud4CARE cluster analysis generated a somatic database of 2270 mutations, investigated to define the colonal evolution of the genomic architecture over time and the level of concordance between Ft-S and Sd-S biopsies. threshold, we observed a slight increase in concordance rate (AF ≥3%, 13.04%; AF ≥10%, 25%-27%, P < 0.01, supplementary CDKN2A  CDK12  RB1  CCND1  CCNE1  CDKN1A  BRCA2  BRCA1  RAD51  BRIP1  C11orf30  FANCF  MLH1  MSH2  ERCC1  TP53  CHEK2  ATM  ATR  FGFR2  IGF1R  PDGFRB  THBS2  MET  ERBB2  EGFR  PIK3CA  PTEN  PPP2R1A  AKT2  MTOR  AKT1  KRAS  BRAF  NF1  ABCB1  TOP1  TOP2A  TOP2B  TUBB3  CDH1  TGFBR2  CTNNB1  BMP7  TGFB3  BAMBI  NOTCH3  WNT1  FN1  COL3A1  LAMC3  CD44  VIM  VCAM1  SNAI1  TWIST1  ZEB1  MYD88  TLR4  DICER1  DROSHA  ID4  FOXL2  FOXM1 Table 1 : grade (red, high grade; green, low grade) and histotype (orange, serous; green, endometroid; gray, mixed; yellow, clear cell; blue, mucinous). Genes are grouped into pathways, depicted by color palette, as described in supplementary Table S1 shows the distribution of the 36 concordant mutations across the 33 patients. As far as early events in HGS-EOC carcinogenesis are concerned, TP53 mutations were the most frequently observed (7 of 19 patients). A cluster of three LG-EOC (20 738, 20 783, 20 821) and one HGS-EOC (20 788) are characterized by concordant mutations in genes BRCA1, BRIP1, PIK3CA, PTEN, AKT2, mTOR, and DROSHA. Pathways concerning HR, and cell signaling through PI3KA-mTOR were the main ones harboring concordant mutations.
mutation profile at Sd-S
Considering the follow-up, analysis of the cohort of patients resistant to primary Pt-therapy showed that their Sd-S biopsies had drug resistance traits, although the data for one patient was unavailable ( Table 2 ). Ten out of 25 patients initially sensitive to first-line chemotherapy presented Sd-S biopsies with resistance attributes, while seven were sensitive. Data for eight patients were unavailable ( Table 2 and supplementary Table S3 .1, available at Annals of Oncology online). It is difficult to draw any conclusion from these data as to the impact of genetic variants on survival or on the development of resistance, although some correlations were observed (supplementary Section 5, available at Annals of Oncology online). Different from supplementary Figure S3 .3, available at Annals of Oncology online, unsupervised cluster analysis at Sd-S revealed two main clusters, MI (14 patients, 42.4%) and MII (19 patients, 57.6%), with intermingled histological and clinical parameters, but with a different mutational landscape ( Figure 4A ). Statistical analysis confirmed that cluster MII is enriched in patients mutated in genes belonging to the HR (P = 0.057, supplementary Table S3 .5, available at Annals of Oncology online), the PI3K signaling (adjusted P = 0.057, supplementary Table S3 .5, available at Annals of Oncology online) and miRNA biogenesis pathways (adjusted P = 0.063, supplementary Table S3 .5, available at Annals of Oncology online). Group MI was mainly enriched in patients mutated in signal transduction pathway genes (adjusted P = 0.057, supplementary Table S3 .5, available at Annals of Oncology online). Box plots shown in Figure 4B depict these differences. Stacked plots in supplementary Figure S3 .4, available at Annals of Oncology online, depict the number of mutations in each gene in cluster MI and MII, respectively, for selected pathways. The low AF ratio for variants in genes belonging to the HR and DNA signaling pathways measured at Sd-S, suggests that, at relapse, tumor biopsies comprise few populations of cells sharing the same alterations (supplementary Figure S3 .5 and supplementary Table S3 .2, available at Annals of Oncology online). It is not known whether these are new mutations acquired after initial therapy or were present at very low levels already at diagnosis and then selected for recurrence.
discussion
The two main findings of our target re-sequencing study are that somatic mutations show a low rate of concordance between primary and recurrent disease, and that the genomic architecture of relapsed disease is less heterogeneous than that of the primary disease. For the clinical management of HGS-EOC, assessing the temporal stability of somatic mutations emerges as a relevant issue. This is in particular the case for genes belonging to the HR pathway, which is now recognized as companion diagnostic tool for the treatment using PARPi [3, 4] . After one or more courses of Pt-based therapy, the decision to treat relapsed disease with PARPi is based on the evaluation of BRCA1/2 status made at primary surgery, when patients are naïve to therapy. What was not yet known is whether these somatic mutations are stable over time, and whether other genes beyond BRCA1/2 could be relevant for therapeutic decisions related to PARPi. The few studies reported so far are inconsistent as far as this issue is concerned. Discrepancies are related to the different technologies used, genes selection criteria, the small size of patients enrolled in the study, as well as the nonuniform time points in the treatment settings.
As to the finding that there is low concordance between primary and recurrent disease, our data are consistent with those obtained by Pennington et al. They analyzed a panel of 30 genes (i.e. BROCA test) in a cohort of 23 matched primary and recurrent pairs of EOC patients [13, 14] . As an early driver event in tumor carcinogenesis, TP53 mutations were found to be more stable over time compared with somatic mutations affecting the HR pathway. In general, they observed a relatively low rate of concordance.
In contrast, Castellarin et al. found that 89% of mutations found by exome sequencing of EOC tumor cells harvested from the ascites of three relapsed patients were already present in matched primary tumors. The authors speculated that recurrent tumors arise from selective persistence or outgrowth of preexisting tumor clones with accumulated new mutations [15] . The reason for this discrepancy is unclear but it might be that cancer cells present in the ascitis are not necessarily representative of the tumor cells present in metastatic nodules. The therapies received by the three patients reported by Castellarin were similar to those given to our patients, as they all included carboplatin and taxol.
A third study reported in a case a high level of concordance between primary and relapsed disease, taken after 42 months, suggesting that populations with stable clonal structure are a feature of long survivorship patients [16] .
As to the second result-the genomic architecture of relapsed disease is less heterogeneous than that of the primary diseasethe reduced mutational load observed at Sd-S ( Figure 3A ) means that most of the somatic mutations called at Ft-S have been under negative selection during multiple rounds of chemotherapy. In other words, Pt-based regimes have killed a large proportion of clones present in the tumor cell population, independent of variance ratios. This issue is exemplified by the ATM/ATR genes. In all Ft-S cases of our series, we found loss of functional mutations in the ATM/ATR genes, with variance ratio above 30%, and very seldom at recurrence. This result suggests that mutations in these genes confer high sensitivity to Pt-based therapy, as cells that expressed the mutated genes were killed by treatment. From a therapeutic perspective, specific inhibitors of these two kinases, currently under development, could be used as potentially useful drugs [17] .
Secondary results worthy of discussion are: (i) patients with LG-EOC could also benefit from treatment with PARPi; (ii) other genes than BRCA1/2 could be used for therapeutic decisions as to treatment with PARPi. It has been assumed up to now that HGS-EOC with germline and somatic BRCA1/2 CDK12  RB1  CCND1  CCNE1  CDKN1A  BRCA2  BRCA1  RAD51  BRIP1  C11orf30  FANCF  MLH1  MSH2  ERCC1  TP53  CHEK2  ATM  ATR  FGFR2  IGF1R  PDGFRB  THBS2  MET  ERBB2  EGFR  PIK3CA  PTEN  PPP2R1A  AKT2   AKT1  KRAS  BRAF  NF1  ABCB1  TOP1  TOP2A  TOP2B  TUBB3  CDH1  TGFBR2  CTNNB1  BMP7  TGFB3  BAMBI  NOTCH3  WNT1  FN1  COL3A1  LAMC3  CD44  VIM  VCAM1  SNAI1  TWIST1  ZEB1  MYD88  TLR4  DICER1  DROSHA  ID4  FOXL2  FOXM1  ARID1A   60  40 mutations are sensitive to PARPi. Consistent with Pennington et al., we observed that loss of functional mutations in the BRCA1/2 genes occurred at similar AF also in LG-EOC, at both Ft-S and Sd-S [14] . If confirmed in further studies, it may be prudent to suggest that PARPi should be evaluated in future clinical trials of patients with both HG-EOC and LG-EOC. In our study, we identified loss of function mutations in our panel in every HR gene, as well as in genes belonging to DNA damage signaling, such as ATM/ATR, that indirectly affect the function of the HR core pathway [18] . In contrast to the current dogma that loss of function mutations in BRCA1/2 increases the response rate to PARPi, our data intimate that other genes can phenocopy the effects of BRCA1/2 mutations. This conclusion suggest that biomarkers of responsiveness to PARPi should not only include analysis of BRCA1/2.
Finally, the TOP2A and TOP2B genes were less frequently mutated at Sd-S than at Ft-S. This result suggests that drugs directed against topoisomerase II such as anthracyclines have a better chance to be effective in second-line than in first-line therapy.
In conclusion, our results suggest that the status of major gene alterations in the primary EOC tumor fails to reflect adequately the status at relapse. Albeit the results are preliminary, they represent proof of principle for the use of longitudinal biopsies in addition to companion diagnostic tools in the clinical management of EOC. 
